Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 131

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines

Zelenetz, Andrew D., Gordon, Leo I., Abramson, Jeremy S., Advani, Ranjana H., Andreadis, Babis, Bartlett, Nancy L., Budde, L. Elizabeth, Caimi, Paolo F., Chang, Julie E., Christian, Beth, DeVos, Sven, Dholaria, Bhagirathbhai, Fayad, Luis E., Habermann, Thomas M., Hamid, Muhammad Saad, Hernandez-Ilizaliturri, Francisco, Hu, Boyu, Kaminski, Mark S., Karimi, Yasmin, Kelsey, Christopher R., King, Rebecca, Krivacic, Susan, LaCasce, Ann S., Lim, Megan, Messmer, Marcus, Narkhede, Mayur, Rabinovitch, Rachel, Ramakrishnan, Praveen, Reid, Erin, Roberts, Kenneth B., Saeed, Hayder, Smith, Stephen D., Svoboda, Jakub, Swinnen, Lode J., Tuscano, Joseph, Vose, Julie M., Dwyer, Mary A., Sundar, Hema·2023·Journal of the National Comprehensive Cancer Network
DOI 10.6004/jnccn.2023.0057
Open this paper in CoChat — free account

Abstract

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2023.0057

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 77

  1. Alaggio R, Amador C, Anagnostopoulos I, The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 2022;36:1720–1748.
  2. Campo E, Jaffe ES, Cook JR, The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229–1253.
  3. Navarro A, Clot G, Royo C, Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307–5316.
  4. Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 2018;132:2722–2729.
  5. Fernàndez V, Salamero O, Espinet B, Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
  6. Ondrejka SL, Lai R, Smith SD, Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121–1127.
  7. Eskelund CW, Dahl C, Hansen JW, TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130:1903–1910.
  8. Obr A, Klener P, Furst T, A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020;191:e103–106.
  9. Ferrero S, Rossi D, Rinaldi A, KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica 2020;105:1604–1612.
  10. Tam CS, Gregory GP, Ku M, Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. Intern Med J 2022;52:1286–1287.
  11. Graf SA, Stevenson PA, Holmberg LA, Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:2323–2328.
  12. Le Gouill S, Thieblemont C, Oberic L, Rituximab after autologous stem cell transplantation in mantle cell lymphoma. N Engl J Med 2017;377:1250–1260.
  13. Klener P, Salek D, Pytlik R, Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E50–53.
  14. Kluin-Nelemans HC, Hoster E, Hermine O, Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248–256.
  15. Hermine O, Jiang L, Walewski J, High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 2023;41:479–484.
  16. Byrd JC, Hillmen P, Ghia P, Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441–3452.
  17. Brown JR, Eichhorst B, Hillmen P, Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319–332.
  18. Wang ML, Jurczak W, Jerkeman M, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482–2494.
  19. Khouri IF, Saliba RM, Okoroji GJ, Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:2630–2635.
  20. Dreyling M, Lenz G, Hoster E, Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–2684.
  21. Zoellner AK, Unterhalt M, Stilgenbauer S, Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021;8:e648–657.
  22. Thieblemont C, Antal D, Lacotte-Thierry L, Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005;104:1434–1441.
  23. Till BG, Gooley TA, Crawford N, Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062–1073.
  24. van’t Veer MB, de Jong D, MacKenzie M, High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.
  25. Metzner B, Müller TH, Casper J, Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 2023;111:220–228.
  26. Wang M, Rule S, Zinzani PL, Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:2762–2766.
  27. Tam CS, Opat S, Simpson D, Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5:2577–2585.
  28. Wang M, Fayad L, Wagner-Bartak N, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716–723.
  29. Wang M, Schuster SJ, Phillips T, Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 2017;10:171.
  30. Wang ML, Blum KA, Martin P, Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739–745.
  31. Jain P, Romaguera J, Srour SA, Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404–411.
  32. Rule S, Jurczak W, Jerkeman M, Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018;32:1799–1803.
  33. McCulloch R, Lewis D, Crosbie N, Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021;193:290–298.
  34. Eyre TA, Walter HS, Iyengar S, Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019;104:e68–71.
  35. Zhao S, Kanagal-Shamanna R, Navsaria L, Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) — outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020;95:623–629.
  36. Awan FT, Schuh A, Brown JR, Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019;3:1553–1562.
  37. Rogers KA, Thompson PA, Allan JN, Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364–2373.
  38. Shadman M, Flinn IW, Levy MY, Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023;10:e35–45.
  39. Wang M, Munoz J, Goy A, Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41:555–567.
  40. Martin P, Maddocks K, Leonard JP, Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:1559–1563.
  41. Jain P, Kanagal-Shamanna R, Zhang S, Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96:E137–140.
  42. Hess G, Dreyling M, Oberic L, Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol 2022;202:749–759.
  43. Munshi PN, Hamadani M, Kumar A, American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther 2021;27:720–728.
  44. Fowler NH, Dickinson M, Dreyling M, Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325–332.
  45. Morschhauser F, Tilly H, Chaidos A, Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433–1442.
  46. Dreyling M, Santoro A, Mollica L, Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362–371.
  47. Flinn IW, Miller CB, Ardeshna KM, DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912–922.
  48. Gopal AK, Kahl BS, de Vos S, PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008–1018.
  49. Gopal AK, Kahl BS, Flowers CR, Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129:3037–3039.
  50. Fowler NH, Samaniego F, Jurczak W, Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:1609–1618.
  51. Richardson NC, Kasamon Y, Pazdur R, The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol 2022;23:563–566.
  52. Philip T, Guglielmi C, Hagenbeek A, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.
  53. Vose JM, Zhang MJ, Rowlings PA, Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
  54. Caballero MD, Pérez-Simón JA, Iriondo A, High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140–151.
  55. Rodriguez J, Caballero MD, Gutierrez A, Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 2004;15:1504–1509.
  56. Shah NN, Ahn KW, Litovich C, Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021;137:1416–1423.
  57. Mounier N, Canals C, Gisselbrecht C, High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012;18:788–793.
  58. Shadman M, Pasquini M, Ahn KW, Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood 2022;139:1330–1339.
  59. Sehn LH, Herrera AF, Flowers CR, Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155–165.
  60. Salles G, Duell J, González-Barca E, Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978–988.
  61. Caimi PF, Ai W, Alderuccio JP, Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790–800.
  62. Kalakonda N, Maerevoet M, Cavallo F, Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511–522.
  63. Van Den Neste E, Schmitz N, Mounier N, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant 2016;51:51–57.
  64. Crump M, Neelapu SS, Farooq U, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800–1808.
  65. Ayers EC, Li S, Medeiros LJ, Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 2020;126:293–303.
  66. Neelapu SS, Jacobson CA, Ghobadi A, Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141:2307–2315.
  67. Schuster SJ, Tam CS, Borchmann P, Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:1403–1415.
  68. Sehgal A, Hoda D, Riedell PA, Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 2022;23:1066–1077.
  69. Abramson JS, Solomon SR, Arnason J, Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675–1684.
  70. Byrne M, Oluwole OO, Savani B, Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e344–351.
  71. Chow VA, Gopal AK, Maloney DG, Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 2019;94:E209–213.
  72. Budde LE, Sehn LH, Matasar M, Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23:1055–1065.
  73. Thieblemont C, Phillips T, Ghesquieres H, Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol 2023;41:2238–2247.
  74. Dickinson MJ, Carlo-Stella C, Morschhauser F, Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220–2231.
  75. Lee DW, Santomasso BD, Locke FL, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638.
  76. Neelapu SS, Tummala S, Kebriaei P, Chimeric antigen receptor T-cell therapy —assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.
  77. Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood 2023;141:2460–2469.

Cited by

See all 131

Metadata

Authors
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., Budde, L. E., Caimi, P. F., Chang, J. E., Christian, B., DeVos, S., Dholaria, B., Fayad, L. E., Habermann, T. M., Hamid, M. S., Hernandez-Ilizaliturri, F., Hu, B., Kaminski, M. S., Karimi, Y., Kelsey, C. R., King, R., Krivacic, S., LaCasce, A. S., Lim, M., Messmer, M., Narkhede, M., Rabinovitch, R., Ramakrishnan, P., Reid, E., Roberts, K. B., Saeed, H., Smith, S. D., Svoboda, J., Swinnen, L. J., Tuscano, J., Vose, J. M., Dwyer, M. A., & Sundar, H.
Affiliations
  • Memorial Sloan Kettering Cancer Center
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Massachusetts General Hospital Cancer Center
  • Stanford Cancer Institute
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • City of Hope National Medical Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • University of Wisconsin Carbone Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • UCLA Jonsson Comprehensive Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • Mayo Clinic Comprehensive Cancer Center
  • St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
  • Roswell Park Comprehensive Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • University of Michigan Rogel Cancer Center
  • Duke Cancer Institute
  • Consultant
  • Dana-Farber/Brigham and Women’s Cancer Center
  • Fox Chase Cancer Center
  • O’Neal Comprehensive Cancer Center at UAB
  • University of Colorado Cancer Center
  • UT Southwestern Simmons Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital
  • Moffitt Cancer Center
  • Fred Hutchinson Cancer Center
  • Abramson Cancer Center at the University of Pennsylvania
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • UC Davis Comprehensive Cancer Center
  • Fred & Pamela Buffett Cancer Center
  • National Comprehensive Cancer Network
Venue
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Published
2023-11
Volume
21
Issue
11
Pages
1118-1131
ISSN
  • 1540-1405
  • 1540-1413
DOI
10.6004/jnccn.2023.0057
Cited by
131
References
3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines. https://app.cochat.ai/papers/10.6004/jnccn.2023.0057
The paper
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., Budde, L. E., Caimi, P. F., Chang, J. E., Christian, B., DeVos, S., Dholaria, B., Fayad, L. E., Habermann, T. M., Hamid, M. S., Hernandez-Ilizaliturri, F., Hu, B., Kaminski, M. S., Karimi, Y., . . . Sundar, H. (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.0057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.